Allergan
Financials
Estimates*
EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|---|
Revenues | - | 14.5b | 14.3b | 14.6b | 13.8b | 14.4b | 14.7b |
% growth | - | - | (1 %) | 2 % | (5 %) | 4 % | 2 % |
EV / revenue | - | 4.9x | 4.3x | 5.0x | 4.2x | 4.0x | 3.9x |
R&D budget | 2.7b | 1.7b | 2.0b | 1.6b | - | - | - |
R&D % of revenue | - | 12 % | 14 % | 11 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | - | ||
N/A | N/A | IPO | |
* | $63.0b | Acquisition | |
Total Funding | - |
Recent News about Allergan
EditAllergan is a global pharmaceutical company that focuses on developing, manufacturing, and commercializing branded pharmaceutical products. The company serves a diverse range of clients including healthcare providers, hospitals, and clinics. Operating primarily in the markets of eye care, medical aesthetics, and neurology, Allergan offers a broad portfolio of products designed to improve patient outcomes and quality of life.
The business model of Allergan revolves around research and development (R&D) to create innovative treatments and therapies. The company invests heavily in clinical trials and regulatory approvals to bring new products to market. Revenue is generated through the sale of prescription medications and medical devices, as well as through partnerships and licensing agreements.
Allergan's market strategy includes targeting high-growth therapeutic areas and leveraging its strong brand recognition to maintain a competitive edge. The company also focuses on expanding its global footprint through strategic acquisitions and collaborations.
Keywords: pharmaceutical, eye care, aesthetics, neurology, branded products, R&D, clinical trials, medical devices, global footprint, strategic acquisitions.